Thymosin alpha-1
Ta1, Thymalfasin, Zadaxin
Approved in more than 35 countries for hepatitis B, and on the FDA's do-not-compound list in the United States. Same molecule, opposite verdicts.
Human trials
Approved as Zadaxin in over 35 countries including China and Italy, mainly for chronic hepatitis B. Not FDA-approved in the United States, and placed on the FDA's Category 2 bulk substances list in 2023, which bars compounding.
What it is
Thymosin alpha-1 is a 28 amino acid peptide originally isolated from the thymus, the gland that trains T cells and then shrinks steadily from adolescence onward. It works upstream of the immune response rather than on any single pathogen, largely through Toll-like receptor signalling, nudging dendritic cells and T cells toward a more coordinated response.
Approved abroad, blocked at home
This is the clearest example on the site of regulatory status depending on geography rather than biology.
As Zadaxin, thymosin alpha-1 is approved in more than 35 countries, principally for chronic hepatitis B, with real randomised trials behind that indication. In the United States it has never been FDA-approved, and in 2023 it landed on the Category 2 bulk substances list alongside BPC-157, which means compounding pharmacies may no longer prepare it.
Both things are true at once. A drug can carry a solid evidence base for one specific indication and still fail to clear a different regulator's bar for general use. It is worth resisting both convenient readings: this is neither an unproven research chemical nor an approved medicine you happen to be buying abroad.
What the evidence actually covers
The trial base is chronic hepatitis B, plus some work in sepsis and as a vaccine adjuvant. It is real, it is randomised, and it is about specific disease states in patients whose immune function is measurably compromised.
Almost nobody in peptide communities is taking it for hepatitis B. The common use is general immune support, resilience during travel, recovery from frequent illness. There are no trials for that, and there is a reasonable prior that a drug which helps a dysregulated immune system does less for one already working fine.
Practical notes
- Autoimmune conditions are the obvious contraindication. If your immune system is already attacking you, amplifying its signalling is the wrong direction.
- The approved regimens are long. Hepatitis protocols run six to twelve months of twice-weekly dosing, which is a different commitment from a two-week course before a trip.
- Sourcing is the usual problem. Zadaxin exists as a real pharmaceutical product in other countries, but what circulates in peptide communities is research-grade material with the identity and sterility questions covered in safety and sourcing.
Side effects and warning signs
Commonly reported
- Injection-site discomfort, the most commonly reported effect
- Transient fatigue or flu-like feeling after dosing
- Generally well tolerated in the hepatitis trials, which are the only large safety datasets
Stop and get medical help
- Autoimmune disease, where deliberately stimulating immune signalling is a genuinely bad idea
- Immunosuppressive therapy after a transplant, where it works directly against the treatment
- Any new or worsening systemic symptom during use
Sources
From the community
Discussion for this compound concentrates in r/Peptidesource and r/PeptideForum.
No threads cached yet.
Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.